Virus Genes

pp 1–10 | Cite as

Linear epitope binding antibodies against GII.3 Norovirus exhibit no histo-blood group antigens (HBGAs) blocking effects

  • Shuhuan Ma
  • Fukun Zhang
  • Lijun Zheng
  • Jinjin Liu
  • Jie Ma
  • Xuhui Chen
  • Zhaojie Yang
  • Wenhui Wang
  • Li Li
  • Mingchen Wang
  • Yuqi HuoEmail author


Noroviruses are leading cause of acute gastroenteritis worldwide. In our previous study, we established an in vitro histo-blood group antigens (HBGAs) binding blockade assay against GII.3 Norovirus virus like particles (VLPs) with trypsin digestion. In this study, we characterized the blocking antibody binding site and epitope type (linear or conformational) by using hyperimmune sera produced against different antigens. VP1 from Jingzhou402 (GII.3, JZ402) strain was expressed by using pGEX-6p-1 expression vector and the insoluble proteins were purified for immunization in rabbit. Previously characterized chimeric VP1-assembled VLPs (GII.4-VP1/GII.3-P2) were used to immunize guinea pig. Peptides reactive with hyperimmune serum against VLPs derived from the VP1 of JZ402 strain were conjugated with BSA and used to immunize rabbits. Hyperimmune sera against above antigens and JZ402 and JZ403 strain-derived VLPs were used to compare their HBGAs blocking effects. Rabbit anti-GST-VP1 and BSA-peptide conjugated hyperimmune sera demonstrated no blocking effects against the binding of GII.3 and GII.4 NoV VLPs to salivary HBGAs. Guinea pig anti-GII.4-VP1/GII.3-P2 hyperimmune serum blocked the binding of trypsin cleaved GII.3 VLPs to salivary HBGAs with no or very weak blocking effects against the binding of GII.4 VLPs to salivary HBGAs. Our data indicated that HBGAs blocking antibodies primarily bound the P2 domain of GII.3 NoV VP1 and their binding epitopes were most probably conformation-dependent.


Noroviruses Major capsid protein Hyperimmune serum Epitopes Blocking antibody 



We thank Qiong Fan, Department of Biochemistry, Institute of Basic Medical Sciences, University of Oslo and Xiaoran Li, Department of Pathology, University of Texas, MD Anderson Cancer Center for editing our manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

Animal experiments were performed in accordance with the guidelines of Chinese Council on Animal Care. The research protocol was approved by Animal Care and Use Committee of the Wuhan Institute of Biological Products (WIBP).


  1. 1.
    Prasad B, Hardy M, Dokland T, Bella J, Rossmann M, Estes M (1999) Science 286:287–290CrossRefGoogle Scholar
  2. 2.
    Prasad B, Rothnagel R, Jiang X, Estes M (1994) J Virol 68:5117–5125Google Scholar
  3. 3.
    Vinjé J (2015) J Clin Microbiol 53:373–381CrossRefGoogle Scholar
  4. 4.
    Bu W, Mamedova A, Tan M, Xia M, Jiang X, Hegde RS (2008) J Virol 82:5340–5347CrossRefGoogle Scholar
  5. 5.
    Cao S, Lou Z, Tan M, Chen Y, Liu Y et al (2007) J Virol 81:5949–5957CrossRefGoogle Scholar
  6. 6.
    Choi J, Hutson A, Estes M, Prasad B (2008) Proc Natl Acad Sci USA 105:9175–9180Google Scholar
  7. 7.
    Chen Y, Tan M, Xia M, Hao N, Zhang X et al (2011) PLoS Pathog 7:e1002152CrossRefGoogle Scholar
  8. 8.
    Lochridge V, Jutila K, Graff J, Hardy M (2005) J Gen Virol 86:2799–2806CrossRefGoogle Scholar
  9. 9.
    Tan M, Huang P, Meller J, Zhong W, Farkas T, Jiang X (2003) J Virol 77:12562–12571CrossRefGoogle Scholar
  10. 10.
    Tan M, Xia M, Cao S, Huang P, Farkas T et al (2008) Virology 379:324–334CrossRefGoogle Scholar
  11. 11.
    Boon D, Mahar J, Abente E, Kirkwood C, Purcell R et al (2011) J Virol 85:8656–8666CrossRefGoogle Scholar
  12. 12.
    Huo Y, Wan X, Ling T, Shen S (2016) Microb Pathog 90:78–83CrossRefGoogle Scholar
  13. 13.
    K S-L ME, K A-B A, dR SA et al (2015) Clin Microbiol Infect 21:874.e1–874.e8CrossRefGoogle Scholar
  14. 14.
    Huo Y, Wang W, Zheng L, Chen X, Shen S, Wang M (2017) Virus Res 240:18–24CrossRefGoogle Scholar
  15. 15.
    Huo Y, Wang W, Ling T, Wan X, Ding L et al (2016) Virus Res 224:1–5CrossRefGoogle Scholar
  16. 16.
    W W, Q JLXCSL W, et al (2018) J Med Virol 90:671–676CrossRefGoogle Scholar
  17. 17.
    Donaldson E, Lindesmith L, Lobue A, Baric R (2008) Immunol Rev 225:190–211CrossRefGoogle Scholar
  18. 18.
    Kumar S, Ochoa W, Kobayashi S, Reddy V (2007) J Virol 81:1119–1128CrossRefGoogle Scholar
  19. 19.
    Rydell G, Nilsson J, Rodriguez-Diaz J, Ruvoën-Clouet N, Svensson L et al (2009) Glycobiology 19:309–320CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Shuhuan Ma
    • 1
  • Fukun Zhang
    • 2
  • Lijun Zheng
    • 1
  • Jinjin Liu
    • 1
  • Jie Ma
    • 1
  • Xuhui Chen
    • 1
  • Zhaojie Yang
    • 1
  • Wenhui Wang
    • 3
  • Li Li
    • 3
  • Mingchen Wang
    • 4
  • Yuqi Huo
    • 1
    Email author
  1. 1.The Sixth People’s Hospital of ZhengzhouZhengzhouPeople’s Republic of China
  2. 2.Changchun Keygen Biological ProductsChangchunPeople’s Republic of China
  3. 3.Wuhan Institute of Biological ProductsWuhanPeople’s Republic of China
  4. 4.Zhengzhou UniversityZhengzhouPeople’s Republic of China

Personalised recommendations